12 Month Price Forecast For APYX
Distance to APYX Price Forecasts
APYX Price Momentum
๐ค Considering Apyx Medical (APYX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 6, 2025 11:00 AM UTC
APYX Analyst Ratings & Price Targets
Based on our analysis of 7 Wall Street analysts, APYX has a consensus that is neutral. The median price target is $3.00, with forecasts ranging from $2.00 to $4.00. Currently, there are 1 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
With APYX currently trading at $1.48, the median price forecast suggests a 102.7% upside. The most optimistic forecast comes from at , projecting a 170.3% upside, while at provides the most conservative target, suggesting a 35.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
APYX Analyst Consensus
APYX Price Target Range
Latest APYX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for APYX.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Oct 17, 2024 | BTIG | Sam Eiber | Neutral | Initiates | $0.00 |
Sep 16, 2024 | JMP Securities | David Turkaly | Market Perform | Reiterates | $0.00 |
Nov 10, 2023 | Stephens & Co. | George Sellers | Overweight | Maintains | $5.00 |
Aug 11, 2023 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $4.50 |
Jul 14, 2023 | Stephens & Co. | George Sellers | Overweight | Initiates | $8.00 |
Jun 15, 2023 | Lake Street | Frank Takkinen | Buy | Maintains | $9.00 |
May 24, 2023 | JMP Securities | David Turkaly | Market Perform | Reiterates | $0.00 |
May 12, 2023 | Lake Street | Frank Takkinen | Buy | Maintains | $6.00 |
Dec 8, 2022 | Lake Street | Frank Takkinen | Buy | Assumes | $5.00 |
Aug 12, 2022 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $12.00 |
Jul 19, 2022 | Lake Street | Kyle Bauser | Buy | Maintains | $17.00 |
May 20, 2022 | Lake Street | Buy | Initiates | $0.00 | |
Aug 13, 2021 | JMP Securities | David Turkaly | Market Outperform | Maintains | $14.00 |
May 12, 2020 | JMP Securities | Market Outperform | Maintains | $5.00 | |
Nov 12, 2019 | Piper Sandler | Overweight | Maintains | $10.00 | |
Nov 12, 2019 | Piper Jaffray | Overweight | Maintains | $0.00 | |
Apr 2, 2019 | JMP Securities | Market Outperform | Maintains | $8.00 |
Stocks Similar to Apyx Medical Corp
The following stocks are similar to Apyx Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Apyx Medical Corp (APYX) Financial Data
Apyx Medical Corp has a market capitalization of $55.71M with a P/E ratio of -2.7x. The company generates $49.03M in trailing twelve-month revenue with a -57.9% profit margin.
Revenue growth is -10.5% quarter-over-quarter, while maintaining an operating margin of -45.7% and return on equity of -110.2%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Apyx Medical Corp (APYX) Company Overview
About Apyx Medical Corp
Develops medical devices using energy technology.
Apyx Medical Corporation generates revenue by designing, developing, and manufacturing advanced energy medical devices, particularly through its Helium Plasma Technology. The company operates in two segments: Advanced Energy, which includes its Helium Plasma Generator for surgical procedures, and Original Equipment Manufacturing (OEM), where it produces devices and accessories for other brands.
The company's products are marketed under the Renuvion name in cosmetic surgery and the J-Plasma name in hospital surgical markets. Apyx Medical was formerly known as Bovie Medical Corporation and rebranded in January 2019. It has a long history since its incorporation in 1982 and is based in Clearwater, Florida.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
252
CEO
Mr. Charles D. Goodwin II
Country
United States
IPO Year
2019
Website
apyxmedical.comApyx Medical Corp (APYX) Latest News & Analysis
A new all-in-one platform for body contouring is being introduced for surgical suites, aiming to enhance efficiency and innovation in the field.
The introduction of an all-in-one platform for body contouring could enhance operational efficiency and attract more clients, potentially boosting revenue for related companies.
Apyx Medical Corporation (NASDAQ: APYX) announced that CEO Charles Goodwin and CFO Matt Hill will attend an upcoming conference.
Leadership presence at conferences can signal confidence and strategic direction, potentially influencing investor sentiment and stock performance for Apyx Medical.
Apyx Medical Corporation (NASDAQ:APYX) held its Q3 2024 earnings call on November 8, 2024, with key executives and analysts participating.
Apyx Medical's Q3 2024 earnings call signals upcoming financial insights and strategic direction, which can influence stock performance and investor sentiment.
Apyx Medical Corporation (NASDAQ: APYX) reported Q3 results for 2024 and updated its financial outlook for 2024 and introduced expectations for 2025.
Apyx Medical's Q3 financial results and updated forecasts signal growth potential, influencing investor sentiment and stock performance in the medical technology sector.
Apyx Medical (APYX) reported a quarterly loss of $0.14 per share, beating the Zacks Consensus Estimate of $0.15 but worsening from a loss of $0.13 per share a year ago.
Apyx Medical's smaller-than-expected loss may signal improving financial performance, potentially boosting investor sentiment and stock price. Year-over-year loss increase could raise concerns.
Apyx Medical Corporation (NASDAQ:APYX) announced a direct offering of 3 million shares at $1.18 each and pre-funded warrants for 2.93 million shares, raising approximately $7 million.
Apyx Medical's $7M capital raise through a direct offering may enhance liquidity and fund growth initiatives, impacting stock performance and investor sentiment.
Frequently Asked Questions About APYX Stock
What is Apyx Medical Corp's (APYX) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Apyx Medical Corp (APYX) has a median price target of $3.00. The highest price target is $4.00 and the lowest is $2.00.
Is APYX stock a good investment in 2025?
According to current analyst ratings, APYX has 1 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.48. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for APYX stock?
Wall Street analysts predict APYX stock could reach $3.00 in the next 12 months. This represents a 102.7% increase from the current price of $1.48. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Apyx Medical Corp's business model?
Apyx Medical Corporation generates revenue by designing, developing, and manufacturing advanced energy medical devices, particularly through its Helium Plasma Technology. The company operates in two segments: Advanced Energy, which includes its Helium Plasma Generator for surgical procedures, and Original Equipment Manufacturing (OEM), where it produces devices and accessories for other brands.
What is the highest forecasted price for APYX Apyx Medical Corp?
The highest price target for APYX is $4.00 from at , which represents a 170.3% increase from the current price of $1.48.
What is the lowest forecasted price for APYX Apyx Medical Corp?
The lowest price target for APYX is $2.00 from at , which represents a 35.1% increase from the current price of $1.48.
What is the overall APYX consensus from analysts for Apyx Medical Corp?
The overall analyst consensus for APYX is neutral. Out of 7 Wall Street analysts, 1 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are APYX stock price projections?
Stock price projections, including those for Apyx Medical Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.